EZH2 is involved in psoriasis progression by impairing miR-125a-5p inhibition of SFMBT1 and leading to inhibition of the TGFβ/SMAD pathway.
EZH2
SFMBT1
TGFβ/SMAD pathway
microRNA-125a-5p
psoriasis
Journal
Therapeutic advances in chronic disease
ISSN: 2040-6223
Titre abrégé: Ther Adv Chronic Dis
Pays: United States
ID NLM: 101532140
Informations de publication
Date de publication:
2021
2021
Historique:
received:
17
06
2020
accepted:
21
12
2020
entrez:
5
5
2021
pubmed:
6
5
2021
medline:
6
5
2021
Statut:
epublish
Résumé
In this study, we aimed to decipher the impact of enhancer of zeste homolog 2 (EZH2) in psoriasis as well as the underlying mechanism. A mouse model of psoriasis was developed by means of imiquimod induction, with the expression of EZH2, microRNA-125a-5p (miR-125a-5p), and SFMBT1 determined. The role of EZH2, miR-125a-5p, and SFMBT1 in malignant phenotypes of HaCaT cells and the development of psoriasis Overexpressed SFMBT1 and EZH2 was detected while miR-125a-5p were downregulated in psoriasis tissues and human keratinocyte (HaCaT) cells. EZH2 increased the levels of IL-17A-induced cytokines and promoted the malignant phenotypes of HaCaT cells. Functionally, EZH2 reduced miR-125a-5p expression while miR-125a-5p targeted SFMBT1 to activate the TGFβ/SMAD pathway Taken together, the results of the current study highlight the ability of EZH2 to potentially inactivate the TGFβ/SMAD pathway
Identifiants
pubmed: 33948156
doi: 10.1177/2040622320987348
pii: 10.1177_2040622320987348
pmc: PMC8053822
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2040622320987348Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Int J Mol Sci. 2020 Feb 13;21(4):
pubmed: 32070069
Arthritis Rheumatol. 2019 Oct;71(10):1681-1690
pubmed: 31106974
Exp Dermatol. 2017 Apr;26(4):359-367
pubmed: 27783430
Cytokine. 2007 Apr;38(1):8-11
pubmed: 17560118
J Dermatol Sci. 2010 Aug;59(2):73-80
pubmed: 20570492
J Biol Chem. 2013 Mar 1;288(9):6238-47
pubmed: 23349461
J Invest Dermatol. 2019 Dec;139(12):2547-2550.e12
pubmed: 31207228
Exp Dermatol. 2020 Jan;29(1):51-60
pubmed: 31630447
Mol Biol Rep. 2011 Aug;38(6):4219-24
pubmed: 21116854
N Engl J Med. 2009 Jul 30;361(5):496-509
pubmed: 19641206
Front Immunol. 2018 Jul 06;9:1549
pubmed: 30034395
J Invest Dermatol. 2017 Oct;137(10):2177-2186
pubmed: 28642156
Cancer Cell Int. 2020 Apr 10;20:117
pubmed: 32308562
J Drugs Dermatol. 2014 Feb;13(2):111-8
pubmed: 24509958
Ann Intern Med. 2018 Apr 3;168(7):ITC49-ITC64
pubmed: 29610923
Lancet. 2015 Sep 5;386(9997):983-94
pubmed: 26025581
J Invest Dermatol. 2011 Jul;131(7):1521-9
pubmed: 21412257
Eur J Dermatol. 2011 Jul-Aug;21(4):552-7
pubmed: 21715244
Cold Spring Harb Perspect Biol. 2016 Sep 01;8(9):
pubmed: 27449815
Br J Dermatol. 2015 Aug;173(2):436-47
pubmed: 25662483
J Clin Invest. 2018 Jun 1;128(6):2551-2568
pubmed: 29757188
Cell Signal. 2018 Sep;49:95-104
pubmed: 29886071
Dermatol Ther. 2020 Nov;33(6):e14221
pubmed: 32827203
Eur J Cancer. 2017 Apr;75:63-72
pubmed: 28214660
Onco Targets Ther. 2019 Sep 12;12:7513-7525
pubmed: 31571904
J Dermatol Sci. 2020 Jan;97(1):9-20
pubmed: 31843230
PLoS One. 2007 Jul 11;2(7):e610
pubmed: 17622355
Am J Respir Cell Mol Biol. 2019 Sep;61(3):322-331
pubmed: 30848657
Cold Spring Harb Perspect Biol. 2016 May 02;8(5):
pubmed: 27141051
Cold Spring Harb Perspect Biol. 2015 Jul 01;7(7):a008144
pubmed: 26134312
J Allergy Clin Immunol. 2017 Feb;139(2):550-561
pubmed: 27568078
J Invest Dermatol. 2017 Sep;137(9):1945-1954
pubmed: 28595995
Int J Mol Sci. 2019 Mar 23;20(6):
pubmed: 30909615
Int J Mol Sci. 2020 Mar 03;21(5):
pubmed: 32138313